Evidence map›Paper›PMID 37811123›Full record

ReviewMicrosystems & nanoengineering2023

Current research status of tumor cell biomarker detection.

Liying Jiang, Xinyi Lin, Fenghua Chen, Xiaoyun Qin, Yanxia Yan, Linjiao Ren, Hongyu Yu, Lingqian Chang, Yang Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Microsystems & nanoengineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Synthesis of AgInSDiscover oncology · 2025
    Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Liying JiangSchool of Electrical and Information Engineering, Zhengzhou University of Light Industry, Zhengzhou, 450002 China.
Xinyi LinSchool of Electrical and Information Engineering, Zhengzhou University of Light Industry, Zhengzhou, 450002 China.
Fenghua ChenSchool of Electrical and Information Engineering, Zhengzhou University of Light Industry, Zhengzhou, 450002 China.
Xiaoyun QinSchool of Electrical and Information Engineering, Zhengzhou University of Light Industry, Zhengzhou, 450002 China.
Yanxia YanSchool of Electrical and Information Engineering, Zhengzhou University of Light Industry, Zhengzhou, 450002 China.
Linjiao RenSchool of Electrical and Information Engineering, Zhengzhou University of Light Industry, Zhengzhou, 450002 China.
Hongyu YuDepartment of Mechanical and Aerospace Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China.ORCID 0000-0002-6899-9346
Lingqian Chang *key Laboratory of Biomechanics and Mechanobiology (Beihang University), Ministry of Education, Beijing Advanced Innovation Center for Biomedical Engineering, School of Biological Science and Medical Engineering, Beihang University, Beijing, 100083 China.
Yang Wang *key Laboratory of Biomechanics and Mechanobiology (Beihang University), Ministry of Education, Beijing Advanced Innovation Center for Biomedical Engineering, School of Biological Science and Medical Engineering, Beihang University, Beijing, 100083 China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the annual increases in the morbidity and mortality rates of tumors, the use of biomarkers for early diagnosis and real-time monitoring of tumor cells is of great importance. Biomarkers used for tumor cell detection in body fluids include circulating tumor cells, nucleic acids, protein markers, and extracellular vesicles. Among them, circulating tumor cells, circulating tumor DNA, and exosomes have high potential for the prediction, diagnosis, and prognosis of tumor diseases due to the large amount of valuable information on tumor characteristics and evolution; in addition, in situ monitoring of telomerase and miRNA in living cells has been the topic of extensive research to understand tumor development in real time. Various techniques, such as enzyme-linked immunosorbent assays, immunoblotting, and mass spectrometry, have been widely used for the detection of these markers. Among them, the detection of tumor cell markers in body fluids based on electrochemical biosensors and fluorescence signal analysis is highly preferred because of its high sensitivity, rapid detection and portable operation. Herein, we summarize recent research progress in the detection of tumor cell biomarkers in body fluids using electrochemical and fluorescence biosensors, outline the current research status of in situ fluorescence monitoring and the analysis of tumor markers in living cells, and discuss the technical challenges for their practical clinical application to provide a reference for the development of new tumor marker detection methods.

Indexed as

BiosensorsSensors

Identifiers

PMID37811123
PMCPMC10556054

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.